Clinical research on rabeprazole triple therapy in the treatment of helicobacter pylori related peptic ulcer

Objective To investigate the clinical effect on rabeprazole triple therapy in the treatment of helicobacter pylori related peptic ulcer. Methods Eighty-four patients with helicobacter pylori related peptic ulcer were selected in the hospital from January 2011 to June 2012, who were randomly divided into two groups. Forty-two patients used omeprazole triple therapy as the control group. Omeprazole 20 mg/time, clarithromycin 500 mg/time, amoxicillin 1 000 mg/time, 2 times/d, course of 7 d, later renamed omeprazole 20 mg/time, 1 time/d, course of 4 weeks. Forty-two patients used rabeprazole triple therapy as the observation group. Rabeprazole 20 mg/time, clarithromycin 500 mg/time, amoxicillin 1 000 mg/time, 2 times/d, course of 7 d, later renamed rabeprazole 20 mg/time, 1 time/d, course of 4 weeks. Symptom relief, peptic ulcer, helicobacter pylori clearance, adverse reaction were compared between two groups at the end of treatment. Results The observation group's symptom relief rate was 88.1%, cure rate was 85.7%, helicobacter pylori clearance rate was 95.2%, which were significantly higher than 69.0%, 66.7%, 81.0% of the control group. The difference was statistically significant (P 0.05). Incidence of adverse reactions (7.1%) in the observation group was lower than that of the control group (19.0%). The difference was not statistically significant (P 0.05). Conclusion Rabeprazole triple therapy in the treatment of helicobacter pylori related peptic ulcer has obvious clinical curative effect, which can obviously relieve the clinical symptoms of patients and improve the cure rate of ulcer and helicobacter pylori eradication rate. That has less adverse reaction. That is worthy of clinical use.